BioSpace News Archive

VBI Vaccines Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,272,728 of its common shares and warrants to purchase up to 2,272,728 common shares, at an offering price of $0.88 per common share and associated warrant.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer.

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) will present at Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18, 2024 at 1:00pm ET.

Oncocyte Corporation, a precision diagnostics company, announced a partnership agreement with Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, for the commercialization of its research use only GraftAssure™ assay, powered by Droplet Digital™ PCR *.

Citius Pharmaceuticals, Inc. today announced that the University of Minnesota Masonic Cancer Center intends to expand their ongoing investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox) in combination with FDA-approved CAR-T products for the treatment of B-cell lymphomas.

Leap Therapeutics, Inc. today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock (“Common Stock”) at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock.

XVIVO Perfusion AB, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech Republic, the results from XVIVO’s clinical trial, NIHP2019, in heart transplantation were presented.

Zymeworks Inc. announced that management will report its first quarter 2024 financial results after market close on May 2, 2024.

West Pharmaceutical Services, Inc. announced that it will release first-quarter financial results before the market opens on Thursday, April 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the results from a Phase 2B clinical study of its lead investigational product ATX101.